Targeting Rho-GTPases in immune cell migration and inflammation

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5491-5506

  Biro, Maté ^a,b   Munoz, Marcia A ^a   Weninger, Wolfgang ^a,b,c  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AR 12286; AZAINDOLE 1; BERBERINE; CCG 1423; CEP 1347; CHS 111; DIMETHYLFASUDIL; EHT 1864; FASUDIL; G ACTIN; IPA 3; K 115; MYOSIN; PT 262; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RKI 983; SAR 407899; SECRAMINE; SNJ 1656; SR 3677; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WF 536; WISKOTT ALDRICH SYNDROME PROTEIN; ZCL 278; ENZYME INHIBITOR; PROTEIN KINASE INHIBITOR; RHO KINASE;

ACTIN FILAMENT; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BRAIN VASOSPASM; CELL MIGRATION; CELL MOTILITY; CYTOSKELETON; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME REGULATION; ERECTILE DYSFUNCTION; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY DISEASE; INTRAOCULAR PRESSURE ABNORMALITY; LEUKOCYTE MIGRATION; LIVER INJURY; LUNG EDEMA; LUNG METASTASIS; NONHUMAN; PROTEIN BINDING; PROTEIN TARGETING; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SYNOVITIS; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; LEUKOCYTE; METABOLISM; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTIN CYTOSKELETON; CELL MOVEMENT; ENZYME INHIBITORS; HUMANS; INFLAMMATION; LEUKOCYTES; MYOSINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES;

EID: 84919334568     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12658     Document Type: Review

References (150)

1. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y, (2006). Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol 406: 554-565.
2. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR, (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29: 1039-1045.
3. Ariel A, Timor O, (2013). Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis. J Pathol 229: 250-263.
4. Atassi MZ, Casali P, (2008). Molecular mechanisms of autoimmunity. Autoimmunity 41: 123-132.
5. Auer M, Hausott B, Klimaschewski L, (2011). Rho GTPases as regulators of morphological neuroplasticity. Ann Anat 193: 259-266.
6. Basso AD, Kirschmeier P, Bishop WR, (2006). Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47: 15-31.
7. Bergert M, Chandradoss SD, Desai RA, Paluch E, (2012). Cell mechanics control rapid transitions between blebs and lamellipodia during migration. Proc Natl Acad Sci U S A 109: 14434-14439.
8. Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, et al. (2013). Cancer risk in immune-mediated inflammatory diseases: IMID and cancer risk. Mol Cancer 12: 98.
9. Breyer J, Samarin J, Rehm M, Lautscham L, Fabry B, Goppelt-Struebe M, (2012). Inhibition of Rho kinases increases directional motility of microvascular endothelial cells. Biochem Pharmacol 83: 616-626.
10. Burridge K, Wennerberg K, (2004). Rho and Rac take center stage. Cell 116: 167-179.
11. Castoreno AB, Smurnyy Y, Torres AD, Vokes MS, Jones TR, Carpenter AE, et al. (2010). Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis. Nat Chem Biol 6: 457-463.
12. Cerione RA, (2004). Cdc42: new roads to travel. Trends Cell Biol 14: 127-132.
13. Chan PM, Manser E, (2012). PAKs in human disease. Prog Mol Biol Transl Sci 106: 171-187.
14. Chang LC, Lin RH, Huang LJ, Chang CS, Kuo SC, Wang JP, (2009). Inhibition of superoxide anion generation by CHS-111 via blockade of the p21-activated kinase, protein kinase B/Akt and protein kinase C signaling pathways in rat neutrophils. Eur J Pharmacol 615: 207-217.
15. Chang LC, Huang TH, Chang CS, Tsai YR, Lin RH, Lee PW, et al. (2011). Signaling mechanisms of inhibition of phospholipase D activation by CHS-111 in formyl peptide-stimulated neutrophils. Biochem Pharmacol 81: 269-278.
16. Charras G, Paluch E, (2008). Blebs lead the way: how to migrate without lamellipodia. Nat Rev Mol Cell Biol 9: 730-736.
17. Charras GT, Hu CK, Coughlin M, Mitchison TJ, (2006). Reassembly of contractile actin cortex in cell blebs. J Cell Biol 175: 477-490.
18. Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, et al. (2011). Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res 71: 1721-1729.
19. Chesarone MA, Goode BL, (2009). Actin nucleation and elongation factors: mechanisms and interplay. Curr Opin Cell Biol 21: 28-37.
20. Connolly M, Veale DJ, Fearon U, (2011). Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis. Ann Rheum Dis 70: 1296-1303.
21. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al. (2008). An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15: 322-331.
22. Desire L, Bourdin J, Loiseau N, Peillon H, Picard V, De Oliveira C, et al. (2005). RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem 280: 37516-37525.
23. Dhaliwal JS, Badejo AM Jr, Casey DB, Murthy SN, Kadowitz PJ, (2009). Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-( (3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J Pharmacol Exp Ther 330: 334-341.
24. Di Gennaro A, Haeggstrom JZ, (2014). Targeting leukotriene B4 in inflammation. Expert Opin Ther Targets 18: 79-93.
25. Ding RY, Zhao DM, Zhang ZD, Guo RX, Ma XC, (2011). Pretreatment of Rho kinase inhibitor inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in mice. J Surg Res 171: e209-e214.
26. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, et al. (2007). Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 320: 89-98.
27. Etienne-Manneville S, Hall A (2002). Rho GTPases in cell biology. Nature 420: 629-635.
28. Evelyn CR, Wade SM, Wang Q, Wu M, Iniguez-Lluhi JA, Merajver SD, et al. (2007). CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther 6: 2249-2260.
29. Evelyn CR, Bell JL, Ryu JG, Wade SM, Kocab A, Harzdorf NL, et al. (2010). Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett 20: 665-672.
30. Fackler OT, Grosse R, (2008). Cell motility through plasma membrane blebbing. J Cell Biol 181: 879-884.
31. Fang X, Yin Y, Chen YT, Yao L, Wang B, Cameron MD, et al. (2010). Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem 53: 5727-5737.
32. Feldmann M, Steinman L, (2005). Design of effective immunotherapy for human autoimmunity. Nature 435 (7042): 612-619.
33. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, et al. (2008). Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem 51: 6642-6645.
34. Ferri N, Corsini A, Bottino P, Clerici F, Contini A, (2009). Virtual screening approach for the identification of new Rac1 inhibitors. J Med Chem 52: 4087-4090.
35. Friedl P, Weigelin B, (2008). Interstitial leukocyte migration and immune function. Nat Immunol 9: 960-969.
36. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q, (2013). Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A 110: 1261-1266.
37. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, et al. (2010). Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25: 144-149.
38. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. (2005). Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391-392.
39. Galli SJ, Tsai M, Piliponsky AM, (2008). The development of allergic inflammation. Nature 454 (7203): 445-454.
40. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y, (2004). Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 101: 7618-7623.
41. Gaston B, (2011). The biochemistry of asthma. Biochim Biophys Acta 1810: 1017-1024.
42. Griffith JW, Luster AD, (2013). Targeting cells in motion: migrating toward improved therapies. Eur J Immunol 43: 1430-1435.
43. Guerriero CJ, Weisz OA, (2007). N-WASp inhibitor wiskostatin nonselectively perturbs membrane transport by decreasing cellular ATP levels. Am J Physiol Cell Physiol 292: C1562-C1566.
44. Hall A, (2012). Rho family GTPases. Biochem Soc Trans 40: 1378-1382.
45. Haller C, Rauch S, Michel N, Hannemann S, Lehmann MJ, Keppler OT, et al. (2006). The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity. J Biol Chem 281: 19618-19630.
46. Hautz T, Brandacher G, Zelger B, Gorantla VS, Lee AW, Pratschke J, et al. (2010). Immunologic aspects and rejection in solid organ versus reconstructive transplantation. Transplant Proc 42: 3347-3353.
47. He Y, Xu H, Liang L, Zhan Z, Yang X, Yu X, et al. (2008). Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 58: 3366-3376.
48. Heasman SJ, Carlin LM, Cox S, Ng T, Ridley AJ, (2010). Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol 190: 553-563.
49. Henry PJ, Mann TS, Goldie RG, (2005). A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 18: 67-74.
50. Hernandez E, De La Mota-Peynado A, Dharmawardhane S, Vlaar CP, (2010). Novel inhibitors of Rac1 in metastatic breast cancer. P R Health Sci J 29: 348-356.
51. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y, (1984). Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036-5041.
52. Holstein SA, Hohl RJ, (2012). Is there a future for prenyltransferase inhibitors in cancer therapy? Curr Opin Pharmacol 12: 704-709.
53. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J, et al. (2013). Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem 288: 8531-8543.
54. Howard J, (2001). Mechanics of motor proteins and the cytoskeleton.
55. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. (2006). Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174-178.
56. Ivetic A, Ridley AJ, (2004). Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 112: 165-176.
57. Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, et al. (1997). Neurotrophic 3,9-bis[ (alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J Med Chem 40: 1863-1869.
58. Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, et al. (2007). Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol 152: 1070-1080.
59. Kawaguchi A, Ohmori M, Fujimura A, (2004). Partial protective effect of Y-27632, a Rho kinase inhibitor, against hepatic ischemia-reperfusion injury in rats. Eur J Pharmacol 493: 167-171.
60. Keren K, Pincus Z, Allen GM, Barnhart EL, Marriott G, Mogilner A, et al. (2008). Mechanism of shape determination in motile cells. Nature 453 (7194): 475-480.
61. Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, Ishizaki T, Aldashev A, (2012). Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur Respir J 39: 496-498.
62. Kovacs EM, Makar RS, Gertler FB, (2006). Tuba stimulates intracellular N-WASp-dependent actin assembly. J Cell Sci 119 (Pt 13): 2715-2726.
63. Lammermann T, Sixt M, (2009). Mechanical modes of 'amoeboid' cell migration. Curr Opin Cell Biol 21: 636-644.
64. Lammermann T, Bader BL, Monkley SJ, Worbs T, Wedlich-Soldner R, Hirsch K, et al. (2008). Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 453 (7191): 51-55.
65. Lee SH, Dominguez R, (2010). Regulation of actin cytoskeleton dynamics in cells. Mol Cells 29: 311-325.
66. Lengfeld J, Wang Q, Zohlman A, Salvarezza S, Morgan S, Ren J, et al. (2012). Protein kinase C delta regulates the release of collagen type I from vascular smooth muscle cells via regulation of Cdc42. Mol Biol Cell 23: 1955-1963.
67. Ley K, Laudanna C, Cybulsky MI, Nourshargh S, (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-689.
68. Li H, Peng W, Jian W, Li Y, Li Q, Li W, et al. (2012a). ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol 11: 65.
69. Li L, Zhang W, Cheng S, Cao D, Parent M, (2012b). Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. Mol Neurobiol 46: 64-77.
70. Li Y, Wu Y, Wang Z, Zhang XH, Wu WK, (2010). Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway. Med Sci Monit 16: BR112-BR118.
71. Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, et al. (2013). FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of NF2-associated schwannomas. J Biol Chem 288: 29105-29114.
72. Ligeti E, Welti S, Scheffzek K, (2012). Inhibition and termination of physiological responses by GTPase activating proteins. Physiol Rev 92: 237-272.
73. Liu C, Li Y, Yu J, Feng L, Hou S, Liu Y, et al. (2013). Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS ONE 8: e54841.
74. Liu M, Gu M, Wu Y, Zhu P, Zhang W, Yin C, et al. (2009). Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. J Surg Res 157: e117-e127.
75. LoGrasso PV, Feng Y, (2009). Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 9: 704-723.
76. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. (2009). Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 54: 676-683.
77. Mackay CR, (2008). Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 9: 988-998.
78. Maksimoska J, Feng L, Harms K, Yi C, Kissil J, Marmorstein R, et al. (2008). Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 130: 15764-15765.
79. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, et al. (1997). Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol Cell Biol 17: 1129-1143.
80. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A, (2002). Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105: 1545-1547.
81. Mellman I, Coukos G, Dranoff G, (2011). Cancer immunotherapy comes of age. Nature 480 (7378): 480-489.
82. Montalvo-Ortiz BL, Castillo-Pichardo L, Hernandez E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, et al. (2012). Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem 287: 13228-13238.
83. Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, et al. (2006). Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 203: 2749-2761.
84. Mrass P, Kinjyo I, Ng LG, Reiner SL, Pure E, Weninger W, (2008). CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity. Immunity 29: 971-985.
85. Muller WA, (2011). Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323-344.
86. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, et al. (2010). Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 107: 9446-9451.
87. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y, (2000). Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 278: C57-C65.
88. Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M, et al. (2003a). Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 52: 319-324.
89. Nakajima M, Katayama K, Tamechika I, Hayashi K, Amano Y, Uehata M, et al. (2003b). WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin Exp Pharmacol Physiol 30: 457-463.
90. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, et al. (2002). The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 8: 328-336.
91. O E, Lee SW, Lee HS, Lim HS, Ahn HY, Shin JC, et al. (2012). Enhancement of endothelial progenitor cell numbers and migration by H1152, a Rho kinase specific inhibitor. Biosci Biotechnol Biochem 76: 172-175.
92. Olson MF, (2008). Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20: 242-248.
93. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ, (2008). Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol 439: 111-129.
94. Pelish HE, Peterson JR, Salvarezza SB, Rodriguez-Boulan E, Chen JL, Stamnes M, et al. (2006). Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol 2: 39-46.
95. Pertz O, (2010). Spatio-temporal Rho GTPase signaling-where are we now? J Cell Sci 123 (Pt 11): 1841-1850.
96. Peterson JR, Lokey RS, Mitchison TJ, Kirschner MW, (2001). A chemical inhibitor of N-WASp reveals a new mechanism for targeting protein interactions. Proc Natl Acad Sci U S A 98: 10624-10629.
97. Peterson JR, Bickford LC, Morgan D, Kim AS, Ouerfelli O, Kirschner MW, et al. (2004). Chemical inhibition of N-WASp by stabilization of a native autoinhibited conformation. Nat Struct Mol Biol 11: 747-755.
98. Pollard TD, Borisy GG, (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell 112: 453-465.
99. Pollard TD, Cooper JA, (2009). Actin, a central player in cell shape and movement. Science 326 (5957): 1208-1212.
100. Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, et al. (2007). 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 72: 1124-1131.
101. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, et al. (2008). Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 19: 2086-2097.
102. Pula G, Poole AW, (2008). Critical roles for the actin cytoskeleton and cdc42 in regulating platelet integrin alpha2beta1. Platelets 19: 199-210.
103. Raftopoulou M, Hall A (2004). Cell migration: Rho GTPases lead the way. Dev Biol 265: 23-32.
104. Renkawitz J, Sixt M, (2010). Mechanisms of force generation and force transmission during interstitial leukocyte migration. EMBO Rep 11: 744-750.
105. Restifo NP, Dudley ME, Rosenberg SA, (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
106. Salbreux G, Charras G, Paluch E, (2012). Actin cortex mechanics and cellular morphogenesis. Trends Cell Biol 22: 536-545.
107. Sasaki Y, Suzuki M, Hidaka H, (2002). The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[ (4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 93: 225-232.
108. Satoh S, Kobayashi T, Hitomi A, Ikegaki I, Suzuki Y, Shibuya M, et al. (1999). Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 80: 41-48.
109. Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, Meurs H, (2008). The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation. Am J Physiol Lung Cell Mol Physiol 295: L214-L219.
110. Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, et al. (2012). Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol 19: 699-710.
111. Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, et al. (2013). Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A 110: 3155-3160.
112. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ, (2007). Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem 282: 35666-35678.
113. Slotta JE, Laschke MW, Menger MD, Thorlacius H, (2008). Rho-kinase signalling mediates endotoxin hypersensitivity after partial hepatectomy. Br J Surg 95: 976-984.
114. Spiering D, Hodgson L, (2011). Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh Migr 5: 170-180.
115. Stavenger RA, Cui H, Dowdell SE, Franz RG, Gaitanopoulos DE, Goodman KB, et al. (2007). Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J Med Chem 50: 2-5.
116. Stengel K, Zheng Y, (2011). Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal 23: 1415-1423.
117. Sun X, Minohara M, Kikuchi H, Ishizu T, Tanaka M, Piao H, et al. (2006). The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 180: 126-134.
118. Surviladze Z, Young SM, Sklar LA, (2012). High-throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors. Methods Mol Biol 827: 253-270.
119. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K, (2008). Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48: 241-247, discussion 247-248.
120. Szczepanowska J, (2009). Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol 56: 225-234.
121. Takayasu M, Suzuki Y, Shibuya M, Asano T, Kanamori M, Okada T, et al. (1986). The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg 65: 80-85.
122. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M, (2008). Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 126: 309-315.
123. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, (2013). Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156: 731-736.
124. Tasaka S, Koh H, Yamada W, Shimizu M, Ogawa Y, Hasegawa N, et al. (2005). Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am J Respir Cell Mol Biol 32: 504-510.
125. Thorlacius K, Slotta JE, Laschke MW, Wang Y, Menger MD, Jeppsson B, et al. (2006). Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury. J Leukoc Biol 79: 923-931.
126. Thrasher AJ, Burns SO, (2010). WASp: a key immunological multitasker. Nat Rev Immunol 10: 182-192.
127. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. (2007). Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 48: 3216-3222.
128. Tsai CC, Liu HF, Hsu KC, Yang JM, Chen C, Liu KK, et al. (2011). 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol 81: 856-865.
129. Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, et al. (2009). Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med 24: 131-138.
130. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (6654): 990-994.
131. Vega FM, Ridley AJ, (2008). Rho GTPases in cancer cell biology. FEBS Lett 582: 2093-2101.
132. Velat GJ, Kimball MM, Mocco JD, Hoh BL, (2011). Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg 76: 446-454.
133. Viaud J, Peterson JR, (2009). An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 8: 2559-2565.
134. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR, (2009). Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol 10: 778-790.
135. Vigil D, Der CJ, (2013) Chapter nine-inhibitors of the ROCK serine/threonine kinases: key effectors of the RhoA small GTPase. In:, Fuyuhiko T, (ed.). The Enzymes, Vol. 33, Inhibitors of the Ras Superfamily G-proteins, Part A. Academic Press: Waltham, pp. 193-212.
136. de Visser KE, Eichten A, Coussens LM, (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
137. Vockel M, Vestweber D, (2013). How T cells trigger the dissociation of the endothelial receptor phosphatase VE-PTP from VE-cadherin. Blood 122: 2512-2522.
138. Wang J, Liu H, Chen B, Li Q, Huang X, Wang L, et al. (2012). RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol 11: 7.
139. Warfel JM, D'Agnillo F, (2011). Anthrax lethal toxin-mediated disruption of endothelial VE-cadherin is attenuated by inhibition of the Rho-associated kinase pathway. Toxins (Basel) 3: 1278-1293.
140. Williams JP, Meyers JA, (2002). Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 8 (21 Suppl.): S664-S681, quiz S682-665.
141. Williams RD, Novack GD, van Haarlem T, Kopczynski C, (2011). Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 152: 834-841 e831.
142. Xu B, Pelish H, Kirchhausen T, Hammond GB, (2006). Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading. Org Biomol Chem 4: 4149-4157.
143. Yamaguchi H, Miwa Y, Kasa M, Kitano K, Amano M, Kaibuchi K, et al. (2006). Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632. J Biochem 140: 305-311.
144. Yi C, Maksimoska J, Marmorstein R, Kissil JL, (2010). Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol 80: 683-689.
145. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, et al. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5: 2158-2164.
146. Yoshida K, Soldati T, (2006). Dissection of amoeboid movement into two mechanically distinct modes. J Cell Sci 119 (Pt 18): 3833-3844.
147. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, et al. (2012). LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 317: 24-32.
148. Zhang X, Shang X, Guo F, Murphy K, Kirby M, Kelly P, et al. (2008). Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A. Blood 112: 1683-1686.
149. Zhao D, Pothoulakis C, (2003). Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 7: 583-592.
150. Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S, (2013). A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS ONE 8: e74924.